# **Epoxomicin**

Key inhibitor for use in proteasome research.

Cell permeable, potent and selective proteasome inhibitor originally isolated from *Actinomycetes* strain based on its potent *in vivo* antitumor activity. More potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin (Prod. No. BML-PI104). Blocks also trypsin-like and PGPH activities of the proteasome. Regulates antigen presentation at non-toxic doses. Effectively inhibits NF-kB activation *in vitro* and potently blocks inflammation *in vivo* in the mouse ear edema assay. The ubiquitin-proteasome system (UPS) and autophagy serve as two complementary, reciprocally regulated protein degradation systems, thus blockade of UPS by Epoxomicin activates autophagy.

Citations: 38

View Online »


## **Ordering Information**

**Order Online** »

**BML-PI127-0100** 100µg

Manuals, SDS & CofA

**View Online »** 



### **Handling & Storage**

**Use/Stability** As indicated on product label or CoA when stored as recommended. Stable for at least

1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up

to 3 months at -20°C.

**Handling** Protect from light. Avoid freeze/thaw cycles.

Long Term Storage -20°C

Shipping Blue Ice

#### Regulatory Status RUO - Research Use Only

#### **Product Details**

**Appearance** Lyophilized. Very thin transparent film.

**CAS** 134381-21-8

Couple Target Proteasome

Couple Type Inhibitor

Formula  $C_{28}H_{50}N_4O_7$ 

MI 14: 3630

**MW** 554.7

Purity ≥95% (HPLC)

Solubility Soluble in DMSO (15mg/ml) or dichloromethane:methanol

(9:1); insoluble in water.

Last modified: May 29, 2024

